Charles River Laboratories Reports Q4 and Full-Year 2024 Results, Eyes 2025 with Caution

On February 19, 2025, Charles River Laboratories International, Inc. (NYSE: CRL) announced its financial results for the fourth quarter and full-year 2024, revealing a mixed performance amid challenging market conditions. The company's fourth-quarter revenue totaled $1.00 billion, representing a slight decrease of 1.1% compared to $1.01 billion in the same period of 2023.

The decrease in revenue was influenced by several factors:

When adjusted for these items, organic revenue experienced a decline of 1.8%. Notably, while the Manufacturing Solutions segment showed organic growth, it was overshadowed by declines in the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments.

The company's GAAP operating margin saw a significant drop to (16.7%) from the previous year's 13.1%. This decline was largely attributed to a non-cash goodwill impairment of $215 million related to the Biologics Solutions reporting unit, which encompasses Biologics Testing and Contract Development and Manufacturing Organization (CDMO) businesses.

Conversely, on a non-GAAP basis, the operating margin improved to 19.9%, up from 19.1%, driven by better performance and lower corporate costs.

For the fourth quarter, Charles River Laboratories reported a GAAP net loss available to common shareholders of $(215.7) million, equating to $(4.22) per share, a stark contrast to the net earnings of $187.1 million, or $3.62 per diluted share, in Q4 2023.

The losses were primarily driven by the aforementioned goodwill impairment and additional losses from certain venture capital investments. In contrast, non-GAAP net income rose to $136.6 million, reflecting a 7.4% increase year-over-year, with diluted earnings per share on a non-GAAP basis reaching $2.66, an increase of 8.1%.

The RMS segment reported revenues of $204.3 million, marking a 4.3% increase from $195.8 million in Q4 2023. The acquisition of Noveprim contributed significantly to this growth, although organic revenue experienced a slight decrease of 0.4%.

The DSA segment faced a decline in revenue, dropping 3.6% to $603.3 million from $625.8 million in the previous year, with organic revenue decreasing by 3.5%. The segment's operating margin also fell sharply, highlighting the challenges faced in maintaining profitability.

The Manufacturing segment reported revenue of $194.9 million, up 1.6% from the prior year. Although the GAAP operating margin decreased significantly due to the goodwill impairment, the non-GAAP margin showed improvement, reflecting operational efficiencies.

For the entirety of 2024, Charles River Laboratories reported a revenue decrease of 1.9% to $4.05 billion, with net income available to common shareholders plummeting 97.8% to $10.3 million. The company's diluted earnings per share on a GAAP basis reflected this downturn, falling to $0.20 from $9.22 in 2023.

Looking ahead, Charles River Laboratories provided cautious guidance for 2025, projecting a revenue decline of 7.0% to 4.5% and organic revenue drop of 5.5% to 3.5%. The company anticipates continued budgetary constraints from global biopharmaceutical clients and expects pricing challenges in the DSA segment.

The company estimates GAAP earnings per share will be between $4.30 and $4.80 for 2025, with non-GAAP EPS forecasted in the range of $9.10 to $9.60. Notably, the company plans to repurchase approximately $350 million in common stock, affirming its commitment to shareholder value despite the current challenges.

As Charles River Laboratories navigates through a transitional period, the company’s leadership remains focused on strategic initiatives to stabilize revenue, enhance operational efficiency, and ultimately emerge as a more robust entity in the biopharmaceutical landscape. The upcoming webcast is set for February 19th at 8:30 a.m. ET, where further insights will be shared regarding the company's future direction and strategies.